Front Page News

Join Us for an Upcoming Webcast about SPINRAZA TM (nusinersen)

December 29, 2016
Posted in , , ,

Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the […]

Read More ›

Biogen Provides Community Statement and Q&A on the Approval of Spinraza for SMA

December 23, 2016
Posted in , ,

Biogen provided the following statement on the approval of Spinraza for SMA: Dear Members of the SMA Community, Today, the SMA community achieved a goal […]

Read More ›

Ionis Pharmaceuticals Issues Community Statement on the Approval of Spinraza

December 23, 2016
Posted in , ,

Ionis Pharmaceuticals has issued the following community statement on the approval of Spinraza for SMA: Dear Members of the SMA Community, Today is a historic […]

Read More ›

FDA Approves Spinraza for SMA

December 23, 2016
Posted in , , ,

On December 23, the FDA announced that it has approved SpinrazaTM (nusinersen) to treat spinal muscular atrophy, making it the first-ever FDA-approved therapy for SMA. […]

Read More ›

Cure SMA Participates in a Special FDA Listening Session

December 19, 2016
Posted in , , ,

Last week, Cure SMA participated in a listening session with FDA Commissioner Robert M. Califf, MD, MACC. The FDA organized the listening session in order […]

Read More ›

Cure SMA Announces Additional Conference Support for Newly Diagnosed Families

December 13, 2016
Posted in , ,

Thanks to the generous funding provided by the Erin Trainor Memorial Fund, Cure SMA is now offering additional support for newly diagnosed families to attend […]

Read More ›

SMA Community Conducts Outreach Visits with Members of Congress

December 12, 2016
Posted in ,

On November 30, members of the SMA community met with 17 different legislative offices— eight from the Senate and nine from the House of Representatives.  […]

Read More ›

The Lancet Publishes Data from Phase 2, Open-Label Trial of Spinraza (Nusinersen) in Infants

December 7, 2016
Posted in , ,

Today, Lancet published results from the Phase 2, open-label trial of nusinersen (Spinraza) in infants. This trial initiated in 2013, and patients continue to receive […]

Read More ›

The Miller McNeil Woodruff Foundation Makes a Generous Contribution to Cure SMA

December 6, 2016
Posted in ,

The Miller McNeil Woodruff Foundation awarded $87,000 to Cure SMA, in order to further research that will lead to a treatment and cure for SMA. Their gift […]

Read More ›

Cure SMA-Funded Researcher, Chad Heatwole, Publishes Paper on Clinical Trial Outcomes in Adults with SMA

December 5, 2016
Posted in ,

Cure SMA-funded researcher, Chad Heatwole, and his team, have published a paper, “What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients”. This project […]

Read More ›
Scroll to Top